These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Differential Effects of Influenza Virus NA, HA Head, and HA Stalk Antibodies on Peripheral Blood Leukocyte Gene Expression during Human Infection. Walters KA; Zhu R; Welge M; Scherler K; Park JK; Rahil Z; Wang H; Auvil L; Bushell C; Lee MY; Baxter D; Bristol T; Rosas LA; Cervantes-Medina A; Czajkowski L; Han A; Memoli MJ; Taubenberger JK; Kash JC mBio; 2019 May; 10(3):. PubMed ID: 31088926 [TBL] [Abstract][Full Text] [Related]
45. Implementing sequence-based antigenic distance calculation into immunological shape space model. Anderson CS; Sangster MY; Yang H; Mariani TJ; Chaudhury S; Topham DJ BMC Bioinformatics; 2020 Jun; 21(1):256. PubMed ID: 32560624 [TBL] [Abstract][Full Text] [Related]
46. High preexisting serological antibody levels correlate with diversification of the influenza vaccine response. Andrews SF; Kaur K; Pauli NT; Huang M; Huang Y; Wilson PC J Virol; 2015 Mar; 89(6):3308-17. PubMed ID: 25589639 [TBL] [Abstract][Full Text] [Related]
47. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies. Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855 [TBL] [Abstract][Full Text] [Related]
48. Two Escape Mechanisms of Influenza A Virus to a Broadly Neutralizing Stalk-Binding Antibody. Chai N; Swem LR; Reichelt M; Chen-Harris H; Luis E; Park S; Fouts A; Lupardus P; Wu TD; Li O; McBride J; Lawrence M; Xu M; Tan MW PLoS Pathog; 2016 Jun; 12(6):e1005702. PubMed ID: 27351973 [TBL] [Abstract][Full Text] [Related]
49. Structure-Guided Creation of an Anti-HA Stalk Antibody F11 Derivative That Neutralizes Both F11-Sensitive and -Resistant Influenza A(H1N1)pdm09 Viruses. Kotani O; Suzuki Y; Saito S; Ainai A; Ueno A; Hemmi T; Sano K; Tabata K; Yokoyama M; Suzuki T; Hasegawa H; Sato H Viruses; 2021 Aug; 13(9):. PubMed ID: 34578314 [TBL] [Abstract][Full Text] [Related]
50. First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes. Guthmiller JJ; Han J; Li L; Freyn AW; Liu STH; Stovicek O; Stamper CT; Dugan HL; Tepora ME; Utset HA; Bitar DJ; Hamel NJ; Changrob S; Zheng NY; Huang M; Krammer F; Nachbagauer R; Palese P; Ward AB; Wilson PC Sci Transl Med; 2021 Jun; 13(596):. PubMed ID: 34078743 [TBL] [Abstract][Full Text] [Related]
51. Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure. Wei CJ; Yassine HM; McTamney PM; Gall JG; Whittle JR; Boyington JC; Nabel GJ Sci Transl Med; 2012 Aug; 4(147):147ra114. PubMed ID: 22896678 [TBL] [Abstract][Full Text] [Related]
52. Development and characterization of a panel of cross-reactive monoclonal antibodies generated using H1N1 influenza virus. Guo CY; Tang YG; Qi ZL; Liu Y; Zhao XR; Huo XP; Li Y; Feng Q; Zhao PH; Wang X; Li Y; Wang HF; Hu J; Zhang XJ Immunobiology; 2015 Aug; 220(8):941-6. PubMed ID: 25708705 [TBL] [Abstract][Full Text] [Related]
53. Therapeutic Administration of Broadly Neutralizing FI6 Antibody Reveals Lack of Interaction Between Human IgG1 and Pig Fc Receptors. Morgan SB; Holzer B; Hemmink JD; Salguero FJ; Schwartz JC; Agatic G; Cameroni E; Guarino B; Porter E; Rijal P; Townsend A; Charleston B; Corti D; Tchilian E Front Immunol; 2018; 9():865. PubMed ID: 29740451 [TBL] [Abstract][Full Text] [Related]
54. Broadening the H5N3 Vaccine Immunogenicity against H5N1 Virus by Modification of Neutralizing Epitopes. Rajesh Kumar S; Chelvaretnam S; Tan Y; Prabakaran M Viruses; 2017 Dec; 10(1):. PubMed ID: 29295514 [TBL] [Abstract][Full Text] [Related]
55. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. DiLillo DJ; Tan GS; Palese P; Ravetch JV Nat Med; 2014 Feb; 20(2):143-51. PubMed ID: 24412922 [TBL] [Abstract][Full Text] [Related]
56. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype. Walz L; Kays SK; Zimmer G; von Messling V J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654 [TBL] [Abstract][Full Text] [Related]
57. Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans. Zhong W; Gross FL; Holiday C; Jefferson SN; Bai Y; Liu F; Katz JM; Levine MZ Viral Immunol; 2016 May; 29(4):259-62. PubMed ID: 26950058 [TBL] [Abstract][Full Text] [Related]
58. Discovering neutralizing antibodies targeting the stem epitope of H1N1 influenza hemagglutinin with synthetic phage-displayed antibody libraries. Tung CP; Chen IC; Yu CM; Peng HP; Jian JW; Ma SH; Lee YC; Jan JT; Yang AS Sci Rep; 2015 Oct; 5():15053. PubMed ID: 26456860 [TBL] [Abstract][Full Text] [Related]
59. Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance against a Broadly Neutralizing Hemagglutinin Stem Antibody. Prachanronarong KL; Canale AS; Liu P; Somasundaran M; Hou S; Poh YP; Han T; Zhu Q; Renzette N; Zeldovich KB; Kowalik TF; Kurt-Yilmaz N; Jensen JD; Bolon DNA; Marasco WA; Finberg RW; Schiffer CA; Wang JP J Virol; 2019 Jan; 93(2):. PubMed ID: 30381484 [TBL] [Abstract][Full Text] [Related]
60. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B. Gong X; Yin H; Shi Y; He X; Yu Y; Guan S; Kuai Z; Haji NM; Haji NM; Kong W; Shan Y Emerg Microbes Infect; 2016 May; 5(5):e51. PubMed ID: 27222326 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]